Search

Showing "11155" results for ""

ICAAC: Dual/mixed tropic virus speeds disease progression as much as tenfold increase in viral load

ICAAC: Gardasil provides some protection against wide spectrum of cancer-causing HPV

ICAAC: Maraviroc failures associated with shifts from R5-tropic to mixed or X4-tropic HIV

ICAAC: Incidence of non-AIDS-defining cancers remains higher for HIV-positive individuals despite HAART

ICAAC: Sharp decline in HIV prevalence reported in pregnant women in rural northern Zimbabwe

ICAAC: Dapivirine safe and tolerable as potential vaginal microbicide; displays potential in combination with other agents

ICAAC: 48-week results show maraviroc still potent in highly treatment-experienced

ICAAC: Gains in limb fat and CD4 counts continue three years after switching from d4T to tenofovir

ICAAC: Cross-resistance to 3TC and FTC develops slowly with entecavir monotherapy

ICAAC: Serious but non-AIDS-defining illnesses more frequent at lower CD4 counts and higher viral loads

Return of nelfinavir's European license recommended

ICAAC: Phase 1 study provides `proof of concept` for PRO 140, a monoclonal CCR5 antibody

ICAAC: No drug interactions found between TMC125 and ritonavir-boosted elvitegravir

Merck HIV vaccine fails, trials halted

Urinary stones a rare side-effect of atazanavir

Sexual transmission of hepatitis C in HIV-positive gay men reported in Australia

HIV replication can continue in the intestines even with successful antiretroviral therapy

PrEP could prevent up to three million HIV infections in ten years in Africa

Receive the latest HIV research and conference news

Showing "11155" results for ""

ICAAC: Dual/mixed tropic virus speeds disease progression as much as tenfold increase in viral load

ICAAC: Gardasil provides some protection against wide spectrum of cancer-causing HPV

ICAAC: Maraviroc failures associated with shifts from R5-tropic to mixed or X4-tropic HIV

ICAAC: Incidence of non-AIDS-defining cancers remains higher for HIV-positive individuals despite HAART

ICAAC: Sharp decline in HIV prevalence reported in pregnant women in rural northern Zimbabwe

ICAAC: Dapivirine safe and tolerable as potential vaginal microbicide; displays potential in combination with other agents

ICAAC: 48-week results show maraviroc still potent in highly treatment-experienced

ICAAC: Gains in limb fat and CD4 counts continue three years after switching from d4T to tenofovir

ICAAC: Cross-resistance to 3TC and FTC develops slowly with entecavir monotherapy

ICAAC: Serious but non-AIDS-defining illnesses more frequent at lower CD4 counts and higher viral loads

Return of nelfinavir's European license recommended

ICAAC: Phase 1 study provides `proof of concept` for PRO 140, a monoclonal CCR5 antibody

ICAAC: No drug interactions found between TMC125 and ritonavir-boosted elvitegravir

Merck HIV vaccine fails, trials halted

Urinary stones a rare side-effect of atazanavir

Sexual transmission of hepatitis C in HIV-positive gay men reported in Australia

HIV replication can continue in the intestines even with successful antiretroviral therapy

PrEP could prevent up to three million HIV infections in ten years in Africa

Receive the latest HIV research and conference news